FBR Capital Raises Price Target on Marvell Technology (MRVL) Following Announced Mobile Platform Restructuring
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Pre-Open Stock Movers 09/25: (BLPH) (SIEN) (NKE) Higher; (INAP) (FINL) (PIR) Lower (more...)
September 25, 2015 9:29 AM EDT
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) 50% HIGHER; announced positive data from an interim analysis of the Company's Phase 2 long-term extension study of INOpulse for the treatment of Pulmonary Arterial Hypertension (PAH) (Part 2 of the Company's Phase 2 trial). The data reinforce the results from Part 1 of the Phase 2 trial and indicate a sustainability of benefit to PAH patients who received INOpulse therapy. Bellerophon also reported today that the U.S. Food and Drug Administration (FDA) has issued a Special Protocol Assessment (SPA) for the Company's... More
Craig-Hallum Upgrades Marvell (MRVL) to Buy
September 25, 2015 8:17 AM EDTCraig-Hallum upgraded Marvell (NASDAQ: MRVL) from Hold to Buy with a price target of $14.00.
For an analyst ratings summary and ratings history on Marvell click here. For more ratings news on Marvell click here.
Shares of Marvell closed at $9.03 yesterday.
... MoreRBC Capital Raises Price Target on Marvell Technology (MRVL) Following Announced Downsize of Mobile Platform
September 25, 2015 7:57 AM EDTRBC Capital reiterated a Sector Perform rating on Marvell (NASDAQ: MRVL), and raised the price target to $10.00 (from $9.00), following announced downsize of the company's mobile platform. While the restructuring initiative will likely be taken as a positive (material reduction in losses)... More
Piper Jaffray Remains Neutral on Marvell Technology (MRVL) Following Announced Restructure of Mobile Business
September 25, 2015 7:46 AM EDTPiper Jaffray maintained a Neutral rating and $14.00 price target on Marvell (NASDAQ: MRVL) following announced plans to restructure mobile business. The company is restructuring the business to focus on more profitable opportunities.
Analyst Ruben Roy commented, "We view MRVL's announced plans to restructure their mobile business... More
Cowen Remains Bullish on Marvell Technology (MRVL) Following Announced Mobile Platform Closing
September 25, 2015 7:10 AM EDTCowen reiterated an Outperform rating and $14.00 price target on Marvell (NASDAQ: MRVL) following announced closing of the company's mobile platform business. It appears that the company was a victim of bad timing in negotiating a sale or spin-off, with increased competition in... More
Susquehanna Remains Neutral on Marvell Technology (MRVL) Following Announced Closing of Handset Business
September 25, 2015 6:46 AM EDTSusquehanna maintained a Neutral rating and $9.00 price target on Marvell (NASDAQ: MRVL) following the announced resolution of its wireless handset business. Unfortunately, rather than finding a buyer for the business, MRVL has made the decision to close it down. The company intends to significantly downsize its mobile organization to refocus its technology on emerging opportunities in IoT, automotive and networking.
Analyst... More
After Hours Stocks Movers 09/24: (BLPH) (NKE) (MRVL) Higher; (INAP) (PIR) (BBBY) (more...)
September 24, 2015 5:53 PM EDTBellerophon Therapeutics, Inc. (Nasdaq: BLPH) 61% HIGHER; announced positive data from an interim analysis of the Company's Phase 2 long-term extension study of INOpulse for the treatment of Pulmonary Arterial Hypertension (PAH) (Part 2 of the Company's Phase 2 trial). The data reinforce the results from Part 1 of the Phase 2 trial and indicate a sustainability of benefit to PAH patients who received INOpulse therapy. Bellerophon also reported today that the U.S. Food and Drug Administration (FDA) has issued a Special Protocol Assessment (SPA) for the Company's Phase 3 PAH program for... More
Market Wrap: Fed Rate Hike May Happen in '15; Durable Orders Slip in August; Caterpillar Trims Outlook, Plans Cost Cuts
September 24, 2015 5:18 PM EDTMarket wrap for September 24th
End of the Day: S&P 500 down 6.5 to 1,932.24; Dow Jones down 16,201.32 to 78.6; Nasdaq down 18.3 to 4,734.48
Market Brief: U.S. markets slipped lower for a second session as worries about issues in the automotive sector hampered European markets amid the Volkswagen emissions scandal.
Caterpillar announced cost reduction plans, which includes substantial job cuts, and trimmed its outlook.
Fed chair Yellen sees a rate hike happening this year.
New home sales came in better than... More
Marvell Technology (MRVL) Announces 17% Reduction in Global Headcount
September 24, 2015 4:23 PM EDTMarvell Technology Group Ltd. (NASDAQ: MRVL) today announced a significant restructuring of its mobile platform business in order to focus the mobile product line on anticipated more profitable opportunities and right-size its expenses in line with corporate targets. Marvell will continue its strong commitment to wireless connectivity such as WiFi and other wireless standards needed to support its strategies in existing markets as well as expanding into emerging opportunities in IoT and automotive.
As approved by the Company's Board of Directors, the Company... More
